Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Pre-Tax Income : $-1.92 Mil (TTM As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cotinga Pharmaceuticals's pretax income for the three months ended in Jan. 2020 was $-0.41 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jan. 2020 was $-1.92 Mil. Cotinga Pharmaceuticals's pretax margin was %.

Cotinga Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Cotinga Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Pre-Tax Income Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Pre-Tax Income

Get a 7-Day Free Trial

-3.09

-3.84

-4.62

-3.83

-2.02

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
Pre-Tax Income	Get a 7-Day Free Trial															-0.21	-0.70	-0.40	-0.41	-0.41

Competitive Comparison of Cotinga Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Pre-Tax Income falls into.

Cotinga Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cotinga Pharmaceuticals's Pretax Income for the fiscal year that ended in Apr. 2019 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-2.055	+	0.042	+	-0.004	+	0	+	0.0010000000000003
	=	-2.02

Cotinga Pharmaceuticals's Pretax Income for the quarter that ended in Jan. 2020 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-0.36	+	-0.015	+	-0.034	+	0	+	0.0010000000000001
	=	-0.41

Pre-Tax Income for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.92 Mil.

Cotinga Pharmaceuticals (OTCPK:COTQF) Pre-Tax Income Explanation

Cotinga Pharmaceuticals's Pretax Margin for the quarter that ended in Jan. 2020 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-0.408	/	0
	=	%

Cotinga Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018